1
← Back to quizzesFree quiz
Bronchiectasis (Dilatation des bronches)
Bronchiectasis, also known as dilatation of the bronchi, is a chronic respiratory condition characterized by irreversible widening of the bronchial lumen, persistent infection, and…
0 / 20
Score: 0%
2
A 25‑year‑old patient with recurrent infections is found to have a dilated bronchus on CT. Which congenital syndrome most likely explains this finding?
3
In the etiological classification of bronchiectasis, which of the following is considered an acquired cause?
4
Which imaging finding is pathognomonic for bronchiectasis on a chest CT scan?
5
A patient with bronchiectasis presents with massive hemoptysis. Which therapeutic option is specifically indicated for this complication?
6
Which of the following laboratory criteria best defines a high‑quality sputum sample for microbiological analysis in bronchiectasis?
7
Which systemic disease is most frequently associated with acquired bronchiectasis in developing countries?
8
In the therapeutic hierarchy for bronchiectasis, which intervention is reserved for localized disease with significant clinical impact?
9
Which of the following best explains why a normal chest X‑ray does not exclude bronchiectasis?
10
A patient with bronchiectasis is found to have a chronic infection with Pseudomonas aeruginosa. Which long‑term therapy is specifically recommended?
11
Which clinical sign is most suggestive of bronchiectasis during physical examination?
12
Which of the following systemic diseases listed is NOT typically associated with bronchiectasis?
13
In the context of bronchiectasis, what is the primary purpose of long‑term macrolide therapy?
14
Which of the following statements best describes the pathophysiological mechanism leading to bronchial dilation in bronchiectasis?
15
A 40‑year‑old patient with a history of recurrent sinus infections is diagnosed with bronchiectasis. Which etiological category does this case most likely belong to?
16
Which of the following is the most appropriate initial antibiotic regimen for an acute exacerbation of bronchiectasis before culture results are available?
17
Which functional test is most useful to assess the impact of bronchiectasis on exercise capacity?
18
Which complication of bronchiectasis is directly linked to chronic infection and can lead to systemic sepsis?
19
Which preventive measure is NOT part of the standard management plan for bronchiectasis patients?
20
In a patient with bronchiectasis and documented alpha‑1 antitrypsin deficiency, which additional pulmonary condition is most likely to coexist?
Understanding Bronchiectasis: Pathophysiology, Diagnosis, and Management
Bronchiectasis, also known as dilatation of the bronchi, is a chronic respiratory condition characterized by irreversible widening of the bronchial lumen, persistent infection, and inflammation. This course provides a comprehensive overview of the disease, integrating key concepts from histology, genetics, imaging, and therapeutic strategies. It is designed for medical students, residents, and healthcare professionals seeking a deeper grasp of bronchiectasis and its clinical implications.
Learning Objectives
- Identify the hallmark histological changes in bronchiectatic airways.
- Differentiate congenital syndromes that predispose to bronchial dilatation.
- Classify acquired versus congenital causes of bronchiectasis.
- Interpret chest CT findings that are pathognomonic for bronchiectasis.
- Apply evidence‑based therapeutic options, including management of massive hemoptysis.
- Recognize criteria for high‑quality sputum samples and the role of systemic diseases in disease development.
- Understand when surgical intervention is appropriate for localized disease.
1. Histological Hallmarks of Bronchiectasis
Bronchiectasis results from a vicious cycle of infection, inflammation, and structural damage. The key histological feature that distinguishes bronchiectatic airways is metaplasia of the epithelium with goblet cell hyperplasia. This change leads to excessive mucus production, impaired mucociliary clearance, and further airway obstruction.
Other microscopic alterations—such as thickening of the basal lamina or loss of smooth muscle—may be present in related disorders but are not the primary hallmark of bronchiectasis.
2. Congenital Syndromes Associated with Bronchial Dilatation
Several inherited conditions predispose individuals to bronchial enlargement. Among the options, Mounier‑Kuhn syndrome (also called tracheobronchomegaly) is the classic congenital cause where the trachea and main bronchi are markedly dilated. This syndrome typically presents in young adults with recurrent infections and characteristic radiologic findings.
Other congenital entities include:
- Kartagener syndrome – primary ciliary dyskinesia with situs inversus; leads to impaired clearance but not primary dilatation.
- Williams‑Campbell syndrome – deficiency of bronchial cartilage, causing airway collapse rather than true dilatation.
- Cystic fibrosis – CFTR mutation causing thick mucus; bronchiectasis is a downstream complication, not the primary congenital abnormality.
3. Acquired Causes: Etiological Classification
Bronchiectasis can be categorized as congenital or acquired. An acquired cause is exemplified by mycobacterial infection (e.g., Mycobacterium avium complex or tuberculosis). Chronic infection leads to parenchymal destruction, loss of bronchial wall integrity, and subsequent dilatation.
In contrast, congenital causes such as Mounier‑Kuhn syndrome, primary ciliary dyskinesia, or cartilage deficiency are not classified as acquired.
4. Imaging: CT Findings That Define Bronchiectasis
High‑resolution computed tomography (HRCT) is the gold standard for diagnosing bronchiectasis. The pathognomonic CT sign is bronchial wall thickening with lack of tapering toward the hilum. This “tram‑track” appearance reflects permanent airway dilation.
Other radiologic patterns—such as pleural effusion, tree‑in‑bud nodules, or ground‑glass opacities—may accompany bronchiectasis but are not diagnostic on their own.
5. Management of Massive Hemoptysis
Massive hemoptysis is a life‑threatening complication of bronchiectasis. The therapeutic modality specifically indicated for this emergency is bronchial artery embolization (BAE). BAE targets the hypertrophied bronchial arteries responsible for bleeding, achieving rapid hemostasis with a high success rate.
While long‑term macrolides, inhaled antibiotics, and chest physiotherapy are essential for chronic disease control, they do not address acute massive bleeding.
6. Sputum Sample Quality for Microbiological Analysis
Accurate identification of pathogenic organisms hinges on obtaining a high‑quality sputum specimen. The optimal laboratory criterion is PMN (polymorphonuclear leukocytes) >25 per high‑power field and epithelial cells . This indicates a specimen rich in inflammatory cells and low in saliva contamination.
Samples with abundant epithelial cells, low leukocyte counts, or arbitrary colony‑forming unit thresholds without cellular assessment are considered suboptimal.
7. Systemic Diseases Linked to Acquired Bronchiectasis in Developing Countries
Among systemic conditions, tuberculosis infection is the most frequent cause of acquired bronchiectasis in low‑ and middle‑income regions. Post‑tubercular scarring and bronchial wall damage predispose patients to chronic airway dilation.
Other autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) can contribute to bronchiectasis but are less prevalent in these settings.
8. Surgical Resection: Indications and Outcomes
While most bronchiectasis cases are managed medically, surgical resection of the affected bronchial segment is reserved for localized disease with significant clinical impact—such as recurrent infections, hemoptysis, or failure of medical therapy.
Indications include:
- Isolated lobar disease refractory to antibiotics and airway clearance techniques.
- Localized massive hemoptysis not controlled by embolization.
- Progressive decline in pulmonary function attributable to a single diseased segment.
Outcomes are favorable when patient selection is appropriate, with improvements in quality of life and reduction in exacerbation frequency.
9. Integrated Therapeutic Hierarchy
Effective management follows a stepwise approach:
- Airway clearance techniques – chest physiotherapy, postural drainage, and oscillatory devices.
- Antibiotic therapy – targeted based on sputum cultures; long‑term macrolides for prophylaxis.
- Anti‑inflammatory agents – inhaled corticosteroids in patients with coexisting asthma or COPD.
- Bronchial artery embolization – for massive hemoptysis.
- Surgical resection – for localized, refractory disease.
Understanding where each intervention fits helps clinicians tailor treatment to individual patient needs.
10. Key Take‑Home Messages
- Bronchiectasis is defined histologically by epithelial metaplasia with goblet cell hyperplasia.
- Mounier‑Kuhn syndrome is the prototypical congenital cause of tracheobronchomegaly.
- Mycobacterial infection exemplifies an acquired etiology.
- CT evidence of non‑tapering bronchi is diagnostic.
- Bronchial artery embolization is the treatment of choice for massive hemoptysis.
- High‑quality sputum samples require >25 PMNs and
- Tuberculosis remains the leading systemic disease linked to acquired bronchiectasis in developing nations.
- Surgical resection is indicated for localized, clinically significant disease.
By mastering these concepts, clinicians can improve diagnostic accuracy, optimize therapeutic decisions, and ultimately enhance outcomes for patients living with bronchiectasis.
